Taiho Oncology and Araris Biotech AG have announced that the FDA has completed its Investigational New Drug review for ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) carrying a monomethyl auristatin E (MMAE) payload, clearing the way for a Phase I dose-escalation trial in non-Hodgkin lymphoma (nHL). The program marks Taiho's first ADC to enter clinical development and the first human test of any asset built on Araris Biotech's AraLinQ conjugation platform, which Taiho Pharmaceutical acquired when it bought the ETH Zurich and Paul Scherrer Institute spinout in March 2025. Specific details on patient enrollment numbers, primary endpoints, and trial duration were not disclosed in the announcement.
ARC-02 targets CD79b, a component of the B-cell receptor signaling complex expressed broadly across B-cell malignancies. The AraLinQ platform attaches MMAE to a defined glutamine residue (Q295) within the antibody's native Fc region via an isopeptide bond, a chemistry the company reports confers high conjugation stability while preserving the pharmacokinetics and effector functions of the unconjugated antibody. The linkers are hydrophilic, which reduces aggregation in aqueous environments, and the platform's branching architecture enables attachment of multiple payload types to a single antibody — a feature not yet deployed in ARC-02 but central to Araris's longer-term differentiation strategy.
Research context
CD79b has been clinically validated as an ADC target in B-cell NHL through polatuzumab vedotin (Polivy, Genentech/Roche), an FDA-approved CD79b-MMAE conjugate that received full approval in 2023 for previously untreated diffuse large B-cell lymphoma in combination with rituximab, cyclophosphamide, hydroxydaunorubicin, and prednisone. ARC-02 shares both the target and the cytotoxic payload with polatuzumab vedotin, meaning Taiho's clinical rationale rests in large part on whether AraLinQ's site-specific, high-stability conjugation chemistry translates into a meaningfully different therapeutic index in patients. Preclinical data cited by Araris suggest the platform maintains antibody function post-conjugation, but human pharmacokinetic and safety data do not yet exist.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article